Semaglutide cuts major kidney complications risk for adults with type 2 diabetes, CKD
Click Here to Manage Email Alerts
Key takeaways:
- During 3.4 years, semaglutide was tied to a 24% reduction in risk for major kidney outcomes.
- Semaglutide benefits were consistent across all categories of eGFR.
SAN DIEGO — Semaglutide was associated with lower risk for major kidney complications for adults with type 2 diabetes and chronic kidney disease without regard to baseline kidney function, data show.
Researchers analyzed data from the multinational FLOW trial on 3,533 adults with type 2 diabetes and varying degrees of CKD. The goal was to assess kidney outcomes by CKD severity. Mean age of patients was 67 years. At baseline, mean eGFR was 47 mL/min/1.73 m² and median urine albumin-creatinine ratio (uACR) was 568 mg/g.
using Glass.Mapper.Sc.Web.Mvc“The FLOW trial is a clinical trial that published earlier this year, and now we are reporting outcomes according to how severe CKD was in this group of patients,” Katherine R. Tuttle, MD, FASN, FACP, FNKF, executive director for research at Providence Inland Northwest Health in Spokane, Washington, and professor of medicine at the University of Washington nephrology division and kidney research institute in Seattle, said during a press briefing at ASN Kidney Week.
“What we learned is that semaglutide reduced the risk of major kidney disease outcomes, cardiovascular events and all-cause mortality in people with type 2 diabetes and CKD. ... We analyzed the kidney outcomes by baseline severity of CKD.”
Patients were randomly assigned to receive either subcutaneous semaglutide 1 mg once weekly or placebo with standard care. The main outcome was persistent kidney failure, eGFR decline greater than 50% or kidney- or cardiovascular-related death.
During a median of 3.4 years of follow-up, semaglutide was associated with a 24% reduction in risk for major kidney outcomes vs. placebo (HR = 0.76; 95% CI, 0.66-0.88). Tuttle and colleagues found beneficial qualities of semaglutide were consistent across all eGFR and uACR categories.
“The bottom line is, from earlier to later stages of CKD, people benefit similarly. The same is true by albuminuria categories. ... The take-home message is there is a consistency of benefit,” Tuttle said. “We can say with certainty that semaglutide saves kidneys, and it safely reduced the risk of major kidney outcomes, irrespective of CKD severity, whether defined by baseline GFR or urine albumin in participants with type 2 diabetes and CKD.”
Collapse
Tuttle KR, et al. SA-OR93. Presented at: ASN Kidney Week; Oct. 24-27, 2024; San Diego.
Click Here to Manage Email Alerts